Rhumbline Advisers Fate Therapeutics Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Rhumbline Advisers holds 159,172 shares of FATE stock, worth $226,024. This represents 0.0% of its overall portfolio holdings.

Number of Shares
159,172
Previous 156,998 1.38%
Holding current value
$226,024
Previous $549,000 52.28%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
BUY
$1.61 - $3.35 $3,500 - $7,282
2,174 Added 1.38%
159,172 $262,000
Q3 2024

Nov 12, 2024
SELL
$3.12 - $5.57 $9,369 - $16,726
-3,003 Reduced 1.88%
156,998 $549,000
Q2 2024

Aug 01, 2024
BUY
$3.26 - $7.08 $51,589 - $112,041
15,825 Added 10.98%
160,001 $524,000
Q1 2024

May 09, 2024
BUY
$3.54 - $8.35 $13,597 - $32,072
3,841 Added 2.74%
144,176 $1.06 Million
Q4 2023

Feb 08, 2024
SELL
$1.65 - $3.94 $11 - $27
-7 Reduced -0.0%
140,335 $524,000
Q3 2023

Nov 09, 2023
BUY
$2.02 - $5.04 $3,300 - $8,235
1,634 Added 1.18%
140,342 $297,000
Q2 2023

Aug 08, 2023
BUY
$4.76 - $6.59 $105,476 - $146,027
22,159 Added 19.01%
138,708 $660,000
Q1 2023

May 11, 2023
BUY
$4.24 - $11.12 $11,057 - $29,000
2,608 Added 2.29%
116,549 $664,000
Q4 2022

Feb 14, 2023
BUY
$9.86 - $23.83 $35,377 - $85,502
3,588 Added 3.25%
113,941 $1.15 Million
Q3 2022

Nov 10, 2022
BUY
$21.04 - $36.06 $188,834 - $323,638
8,975 Added 8.85%
110,353 $2.47 Million
Q2 2022

Aug 11, 2022
BUY
$17.78 - $42.39 $213,288 - $508,510
11,996 Added 13.42%
101,378 $2.51 Million
Q1 2022

May 12, 2022
BUY
$29.67 - $60.28 $22,489 - $45,692
758 Added 0.86%
89,382 $3.47 Million
Q4 2021

Feb 10, 2022
SELL
$47.84 - $64.34 $145,864 - $196,172
-3,049 Reduced 3.33%
88,624 $5.19 Million
Q3 2021

Nov 12, 2021
BUY
$59.27 - $95.73 $125,000 - $201,894
2,109 Added 2.35%
91,673 $5.43 Million
Q2 2021

Aug 05, 2021
BUY
$67.25 - $92.52 $2,488 - $3,423
37 Added 0.04%
89,564 $7.77 Million
Q1 2021

May 06, 2021
SELL
$72.16 - $117.4 $414,054 - $673,641
-5,738 Reduced 6.02%
89,527 $7.38 Million
Q4 2020

Feb 10, 2021
BUY
$38.09 - $100.95 $223,626 - $592,677
5,871 Added 6.57%
95,265 $8.66 Million
Q3 2020

Nov 12, 2020
SELL
$30.41 - $40.5 $410,352 - $546,507
-13,494 Reduced 13.12%
89,394 $3.57 Million
Q2 2020

Aug 13, 2020
BUY
$20.21 - $35.23 $301,290 - $525,208
14,908 Added 16.94%
102,888 $3.53 Million
Q1 2020

May 06, 2020
BUY
$17.28 - $31.88 $56,851 - $104,885
3,290 Added 3.88%
87,980 $1.95 Million
Q4 2019

Feb 05, 2020
BUY
$13.39 - $20.73 $92,056 - $142,518
6,875 Added 8.84%
84,690 $1.66 Million
Q3 2019

Oct 23, 2019
BUY
$15.47 - $22.5 $11,153 - $16,222
721 Added 0.94%
77,815 $1.21 Million
Q2 2019

Aug 14, 2019
SELL
$15.61 - $20.44 $48,796 - $63,895
-3,126 Reduced 3.9%
77,094 $1.57 Million
Q1 2019

May 01, 2019
BUY
$13.15 - $18.71 $11,059 - $15,735
841 Added 1.06%
80,220 $1.41 Million
Q4 2018

Jan 31, 2019
BUY
$11.48 - $16.98 $405,416 - $599,648
35,315 Added 80.14%
79,379 $1.02 Million
Q3 2018

Nov 07, 2018
SELL
$8.75 - $16.29 $26,687 - $49,684
-3,050 Reduced 6.47%
44,064 $718,000
Q2 2018

Aug 06, 2018
BUY
$9.16 - $13.48 $24,988 - $36,773
2,728 Added 6.15%
47,114 $534,000
Q1 2018

May 02, 2018
BUY
$6.3 - $13.77 $68,959 - $150,726
10,946 Added 32.73%
44,386 $433,000
Q4 2017

Feb 09, 2018
SELL
$3.94 - $6.64 $31,862 - $53,697
-8,087 Reduced 19.47%
33,440 $204,000
Q3 2017

Nov 06, 2017
BUY
$2.6 - $4.31 $107,970 - $178,981
41,527
41,527 $164,000

Others Institutions Holding FATE

# of Institutions
167
Shares Held
108M
Call Options Held
79.2K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $138M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email